| Market Capitalization (Millions $) |
2,041 |
| Shares
Outstanding (Millions) |
51 |
| Employees |
398 |
| Revenues (TTM) (Millions $) |
292 |
| Net Income (TTM) (Millions $) |
21 |
| Cash Flow (TTM) (Millions $) |
30 |
| Capital Exp. (TTM) (Millions $) |
14 |
Business Description
Vericel Corporation is a publicly traded biopharmaceutical company that focuses on developing and commercializing cell therapy products that repair or regenerate human tissue.
The company is headquartered in Cambridge, Massachusetts, and has facilities in Michigan and California.
Vericel's flagship product is called MACI, which stands for Matrix-Induced Autologous Chondrocyte Implantation.
This is a regenerative medicine treatment for patients with knee cartilage damage or disorders.
MACI involves harvesting a patient's own healthy cartilage cells, multiplying them in a laboratory, and then implanting them into the affected area of the knee.
MACI received FDA approval in 2016 and has since been used in thousands of patients.
In addition to MACI, Vericel also sells Epicel, which is a cell-based therapy for treating severe burns.
Epicel involves taking a small sample of a patient's own healthy skin cells, multiplying them in a laboratory, and then grafting them onto the burn wound.
Epicel has been used in over 1,000 patients and is the only FDA-approved cell therapy for the treatment of severe burns.
Vericel has a robust research and development pipeline focused on cell therapy products that target cardiac, pulmonary, and neurological diseases.
The company is committed to advancing science and technology to bring innovative treatments to patients suffering from debilitating conditions.
Overall, Vericel Corporation is a leading player in the field of regenerative medicine, with a focus on developing cell-based therapies that improve patients' quality of life.
Company Address: 64 Sidney Street Cambridge 2139 MA
Company Phone Number: 588-5555 Stock Exchange / Ticker: NASDAQ VCEL
|
1.11% 
0.02 %